Robotic transareolar mitral valve repair

2021 ◽  

In recent years, the treatment of mitral valve disease with robotic surgery has been increasingly successful, having produced excellent postoperative results and significant cost-savings. However, minimal experience exists with robotic mitral valve repair using transareolar access. We demonstrate mitral valve repair using the DaVinci Robot Xi through a transareolar approach, showing the technical details of our surgical technique.

BJS Open ◽  
2021 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
Arian Arjomandi Rad ◽  
Keerthana Jayaraajan ◽  
Ridhaa Remtulla ◽  
Ghulam Mustafa Majeed ◽  
Omer Ammar ◽  
...  

Abstract Objectives For the first time this study carried out a cost-utility analysis comparing open surgical repair versus robotic minimally invasive surgical repair for Mitral Regurgitation. The respective benefits and costs of each treatment option gained from data in published literature have been analysed and subsequent suggestions for the allocation of resources and treatment recommendation will be offered. Methods The analysis was performed by including intraoperative and post-operative costs of the interventions and costs of the most prevalent complications associated with each operation. Thus, the Quality Adjusted Life Years (QALYs) calculated will guide the decision of resource allocation by assessing whether the added cost of robotic surgery is justified given the NICE (National institute of Clinical Excellence) threshold of £30,000/QALY. The choice of perspective taken is through the lens of the British National Healthcare System. Results The Incremental cost-effectiveness ratio (ICER) calculated was £4781.44/QALY. This ICER shows that if robotic surgery was to become gold standard, the NHS would be paying £4781.44/QALY gained per patient. Considering robotic surgery is associated with fewer complications for patients but also has a cost per QALY below the NICE threshold of £30,000/QALY, it seems that this is a fitting alternative to open heart mitral valve repair. After a sensitivity analysis accounting for the initial robotic capital investment the ICER resulted to £22,379.94/QALY, still below NICE’s threshold. Conclusion Our results have shown that robotic assisted minimally invasive repair of the mitral valve is a cost-effective option and can be implemented in the British national healthcare setting.


2019 ◽  
Vol 11 (4) ◽  
pp. NP213-NP216
Author(s):  
Dennis VanLoozen ◽  
Michael A. Jensen ◽  
William A. Lutin ◽  
Anastasios C. Polimenakos

Hammock mitral valve (MV) repair is historically technically difficult with a guarded prognosis. Surgical experience is extremely limited and variable outcomes are reported. The perioperative strategy and technical details of hammock MV repair in an infant who presented with severe mitral stenosis are described and review of the existing literature was undertaken.


2019 ◽  
Vol 15 (4) ◽  
pp. 439-445
Author(s):  
Aleksejus Zorinas ◽  
Artūras Lipnevicius ◽  
Viktorija Bleizgytė ◽  
Vilius Janušauskas ◽  
Daina Liekienė ◽  
...  

2021 ◽  
Vol 10 (22) ◽  
pp. 5439
Author(s):  
Antonio Piperata ◽  
Olivier Busuttil ◽  
Nicolas d’Ostrevy ◽  
Jean-Luc Jansens ◽  
Saud Taymoor ◽  
...  

(1) Background: Although transcatheter technology is rapidly growing and represents a promising strategy, the surgical approach remains the best way to repair a degenerative mitral valve regurgitation. In this context, robotic surgery is technologically the most advanced method of minimally invasive mitral valve repair. The aim of this study is to present the preliminary results of the initial single-center experience with a new robotic mitral valve repair program. (2) Methods: We retrospectively reviewed the records of patients who underwent robotic mitral valve repair at our Institution between January and September 2021. (3) Results: A total of 29 patients underwent mitral valve repair with annuloplasty and chordal implantation to treat degenerative mitral regurgitation. The procedure’s success was achieved in 97% of patients. The 30-day cardiac-related mortality was 0%. The median CPB and cross-clamp times were 189 and 111 min, respectively, with a progressive reduction from the beginning of the robotic program. (4) Conclusions: Considering all the limitations related to the small sample, the presented results of robotic mitral valve repair appear to be encouraging and acceptable. A careful patient selection, a dedicated team, and a robust experience in surgical mitral valve repair are the fundamentals to start a new robotic mitral surgery program.


1991 ◽  
Vol 9 (2) ◽  
pp. 315-327 ◽  
Author(s):  
Kwok L. Yun ◽  
D. Craig Miller

Sign in / Sign up

Export Citation Format

Share Document